RuiXin Medical Launches New AngioQFA100 and RuiXin Score 2.0, Advancing Comprehensive Coronary Functional Assessment

In the forefront exploration of the medical and health field, RaysightMed has once again taken a solid step forward, leading a new chapter in medical technology. On December 31st, RaysightMed held an internal launch event for its new product in Shenzhen, officially releasing the angiography product AngioQFA100 and the fully upgraded RuiXin Score 2.0 version.

At the start of the event, Zheng Lingxiao, CEO of RaysightMed, delivered the opening speech. He stated: "We have officially launched the new product AngioQFA100 and the upgraded version 2.0 of the RayScore. Excitingly, AngioQFA100 has successfully obtained Class III certification in the past week, integrating both FFR and IMR functions.More in line with the new model of current coronary heart disease diagnosis and treatment: achieving a new transformation from单纯的 ‘epicardial’ coronary functional assessment to a comprehensive ‘epicardial + microcirculation’ coronary functional assessment."To bring patients a more precise, non-invasive, and comprehensive diagnosis and treatment experience."

RaysightMed CEO Zheng Lingxiao Delivers Opening Speech

Subsequently, Dr. Hongzhi Lan, Chief Scientist and Co-founder of RaysightMedUnveiled and provided a detailed introduction of the new product. He mentioned that as a one-stop coronary macro + micro functional assessment system, the launch of RaysightMed's AngioQFA100 is of milestone significance.This marks RaysightMed's product type officially entering the interventional surgery field from non-invasive diagnosis, expanding its product layout from software to an integrated hardware-software solution for coronary heart disease, achieving a significant leap.

RaysightMed Chief Scientist Dr. Hongzhi Lan Unveils New Product

RaysightMed's AngioQFA100 innovatively integrates artificial intelligence technology withRapid Simulation of Analog CircuitsTechnology,With four major advantages: more precise, more comprehensive, more flexible, and faster.Specifically, AngioQFA100 utilizes single/multi-image mode 3D modeling, supports multi-branch coronary artery analysis, and significantly enhances analytical performance through specific blood pressure acquisition, particularly improving the sensitivity of gray zone lesions. At the same time, using this product allows for obtaining both FFR and IMR in a single analysis, providing a comprehensive assessment of coronary function from macro to micro levels. Notably, AngioQFA100 is the first to feature a Bluetooth pressure acquisition device, enabling convenient operation outside the catheter lab and substantially reducing radiation exposure for physicians during work. It completes simulation calculations in just 10 seconds and achieves full-process analysis within 3-5 minutes, greatly enhancing diagnostic efficiency and providing timely support for clinical decision-making. Prospective clinical studies have shown that RaysightMed's FFR™, IMR results are in good agreement with invasive gold standards.Accuracy, sensitivity, and specificity all reach over 95%.。

RaysightMed Chief Scientist Dr. Hongzhi Lan Introduces New Product

The all-new upgraded RaysightMed Score 2.0 supports fully automatic CT-FFR analysis, reducing manual intervention, with efficient processing, high pass rates, and reliable results. Its launchNext-Generation Intelligent Interaction Features, providing more semi-automatic auxiliary editing tools and comprehensively optimizing the quality inspection process. At the same time, the productAdded key lesion parameters such as △FFR, APS, and WSS., Multi-dimensional assessment of coronary plaque development and rupture risk. Compared with the previous generation product, RaysightMed Score 2.0 breaks the configuration threshold, compatible with ordinary computers in radiology departments, achieving a dual leap in functionality and user experience. Whether for scientific research or clinical application, RaysightMed Score 2.0 will bring users an unprecedented experience and value.

Dr. Ma Jun, CTO and Co-founder, also expressed confidence and anticipation for the new product launch online.He mentioned: "We look forward to these two new products from RaysightMed helping doctors diagnose and treat coronary heart disease more accurately, bringing greater benefits to patients, and contributing to the diagnosis and treatment of coronary heart disease in China and even the world."

RaysightMed ImagingAngioQFA100

Event Celebration Site

This new product launch not only demonstrates RaysightMed's technical strength but also its firm commitment to the future of healthcare. RaysightMed will continue to focus on providing integrated AI + surgical robot hardware and software solutions, continuously leveraging cutting-edge technologies to empower the medical industry, offering doctors the brain, eyes, and hands for cardiovascular and cerebrovascular treatment, ensuring every blood vessel receives early diagnosis and precise treatment.